Literature DB >> 8111769

Percutaneous transluminal coronary angioplasty in patients with severely depressed left ventricular function.

K Reynen1, B Kunkel, R Gansser, K Bachmann.   

Abstract

Among nearly 2,000 consecutive percutaneous transluminal coronary angioplasty (PTCA) patients, 42 patients (36 male, 6 female; mean age 60 +/- 11 years) with mainly unstable angina had ejection fractions of < or = 35% (mean 30 +/- 5%). All patients had previous myocardial infarctions; 31 (= 74%) had multivessel disease. Successful procedure was achieved in 35 of the 42 (= 83%) patients, 31 of 35 (= 89%) stenoses could be successfully dilated and 9 of 15 (= 60%) occlusions reopened. In-hospital mortality was 2.4%. Follow-up angiography in 22 of the 35 patients who had been successfully treated showed significant improvement of ejection fraction from 29 +/- 5 to 36 +/- 7%. At clinical follow-up 19 +/- 14 months (2-53 months) after the procedure, nearly all surviving patients were in anginal class I or II, 5 had died from cardiac and 1 from noncardiac causes. Thus, PTCA in patients with severely depressed left ventricular function shows acceptable acute results; attenuation of ventricular dysfunction and continued symptomatic improvement can be achieved. However, late outcome is significantly worse than in patients with normal ventricular function.

Entities:  

Mesh:

Year:  1993        PMID: 8111769     DOI: 10.1159/000175992

Source DB:  PubMed          Journal:  Cardiology        ISSN: 0008-6312            Impact factor:   1.869


  2 in total

1.  Procedural results of coronary angioplasty but not late mortality have improved in patients with depressed left ventricular function.

Authors:  J Lindsay; G Grasa; E E Pinnow; G Plude; A D Pichard
Journal:  Clin Cardiol       Date:  1999-08       Impact factor: 2.882

2.  Short- and long-term outcomes of percutaneous coronary intervention in patients with low, intermediate and high ejection fraction.

Authors:  M Alidoosti; M Salarifar; A M Zeinali; S E Kassaian; M R Dehkordi; M S Fatollahi
Journal:  Cardiovasc J Afr       Date:  2008 Jan-Feb       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.